The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation

被引:277
作者
Cowan-Jacob, SW [1 ]
Fendrich, G
Manley, PW
Jahnke, W
Fabbro, D
Liebetanz, J
Meyer, T
机构
[1] Novartis Inst Biomed Res, Discovery Technol, CH-4056 Basel, Switzerland
[2] Novartis Inst Biomed Res, Oncol Res Dept, CH-4056 Basel, Switzerland
关键词
D O I
10.1016/j.str.2005.03.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The regulation of the activity of Abl and Src family tyrosine kinases is mediated by intramolecular interactions between the SH3, SH2, and kinase (SH1) domains. We have determined the crystal structure of an unphosphorylated form of c-Src in which the SH2 domain is not bound to the C-terminal tail. This results in an open structure where the kinase domain adopts an active conformation and the C terminus binds within a hydrophobic pocket in the C-terminal lobe. NMR binding studies support the hypothesis that an N-terminal myristate could bind in this pocket, as observed for Abl, suggesting that c-Src may also be regulated by myristate binding. In addition, the structure contains a des-methyl analog of the antileukemia drug imatinib (STI571; Gleevec). This structure reveals why the drug shows a low affinity for active kinase conformations, contributing to its excellent kinase selectivity profile.
引用
收藏
页码:861 / 871
页数:11
相关论文
共 48 条
[1]   A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase [J].
Atwell, S ;
Adams, JM ;
Badger, J ;
Buchanan, MD ;
Feil, IK ;
Froning, KJ ;
Gao, X ;
Hendle, J ;
Keegan, K ;
Leon, BC ;
Müller-Dieckmann, HJ ;
Nienaber, VL ;
Noland, BW ;
Post, K ;
Rajashankar, KR ;
Ramos, A ;
Russell, M ;
Burley, SK ;
Buchanan, SG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (53) :55827-55832
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]   Structure and regulation of Src family kinases [J].
Boggon, TJ ;
Eck, MJ .
ONCOGENE, 2004, 23 (48) :7918-7927
[4]   Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].
Capdeville, R ;
Buchdunger, E ;
Zimmermann, J ;
Matter, A .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502
[5]   Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment [J].
Cowan-Jacob, SW ;
Guez, V ;
Fendrich, G ;
Griffin, JD ;
Fabbro, D ;
Furet, P ;
Liebetanz, J ;
Mestan, J ;
Manley, PW .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (03) :285-299
[6]   The molecular biology of chronic myeloid leukemia [J].
Deininger, MWN ;
Goldman, JM ;
Melo, JV .
BLOOD, 2000, 96 (10) :3343-3356
[7]   2 BINDING ORIENTATIONS FOR PEPTIDES TO THE SRC SH3 DOMAIN - DEVELOPMENT OF A GENERAL-MODEL FOR SH3-LIGAND INTERACTIONS [J].
FENG, SB ;
CHEN, JK ;
YU, HT ;
SIMON, JA ;
SCHREIBER, SL .
SCIENCE, 1994, 266 (5188) :1241-1247
[8]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880
[9]   A myristoyl/phosphotyrosine switch regulates c-Abl [J].
Hantschel, O ;
Nagar, B ;
Guettler, S ;
Kretzschmar, J ;
Dorey, K ;
Kuriyan, J ;
Superti-Furga, G .
CELL, 2003, 112 (06) :845-857
[10]   Molray -: a web interface between O and the POV-Ray ray tracer [J].
Harris, M ;
Jones, TA .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2001, 57 :1201-1203